CSIMarket
 
Catalent Inc   (CTLT)
Other Ticker:  
 
 
Price: $55.9600 $0.18 0.323%
Day's High: $56.16 Week Perf: -1.69 %
Day's Low: $ 55.57 30 Day Perf: -1.31 %
Volume (M): 1,943 52 Wk High: $ 60.20
Volume (M$): $ 108,725 52 Wk Avg: $46.15
Open: $56.01 52 Wk Low: $31.45



 Market Capitalization (Millions $) 10,202
 Shares Outstanding (Millions) 182
 Employees 19,000
 Revenues (TTM) (Millions $) 4,098
 Net Income (TTM) (Millions $) -1,302
 Cash Flow (TTM) (Millions $) -213
 Capital Exp. (TTM) (Millions $) 437

Catalent Inc
Catalent Inc. is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It was founded in 2007 and is headquartered in Somerset, New Jersey, United States. Catalent has a global presence with more than 35 sites across North America, Europe, and Asia-Pacific regions.

The company offers a wide array of services, including drug development, clinical trial solutions, analytical testing, drug delivery technologies, and manufacturing solutions. Catalent specializes in creating innovative technologies that enhance drug delivery, bioavailability, and therapeutic performance, making it possible to efficiently develop and bring life-changing treatments to market.

Catalent deals with a broad range of pharmaceutical clients that rely on them for customized solutions to their unique drug development requirements, with a focus on quality, efficiency, and speed. Their clients include leading pharmaceutical companies, biotech firms, and small to mid-sized pharmaceutical companies that seek end-to-end drug development services.

The company operates under four business segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment develops and manufactures a wide range of solid and semi-solid dose forms of drugs, including softgels, capsules, and tablets. The Biologics segment offers gene therapy, biomanufacturing, and drug development services to biotechnology companies.

The Oral and Specialty Delivery segment is responsible for developing delivery technologies that can enhance oral dosage form efficacy, stability, and performance. This segment produces OptiDose drug delivery systems, which blend drug and excipients into uniform granules that can be compressed into tablets. The Clinical Supply Services segment is responsible for ensuring global clinical trial supply chains operate efficiently to ensure safe and efficient delivery of drugs and therapies.

Catalent is committed to sustainability and environmentally responsible practices in all its operations. It partners with clients to implement greener manufacturing processes using eco-friendly materials and technologies that reduce energy consumption and enable waste reduction. The company has numerous partnerships with academic institutions and leading industry organizations to improve global health outcomes.

In conclusion, Catalent Inc. is a leading player in the drug development and manufacturing industry, offering advanced delivery technologies, development, and analytical testing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It has a highly skilled and experienced team of experts, a global footprint and a commitment to sustainability and green manufacturing processes.


   Company Address: 14 Schoolhouse Road Somerset, 8873 NJ
   Company Phone Number: 537-6200   Stock Exchange / Ticker: NYSE CTLT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Catalent's Commitment to Corporate Responsibility: Progress, Initiatives, and Future Commitments

Published Thu, Mar 7 2024 1:00 PM UTC

Catalent, Inc. (NYSE: CTLT), the global leader in facilitating the development and supply of innovative treatments for patients worldwide, has recently released its fifth annual Corporate Responsibility Report for fiscal year 2023. This report showcases the significant progress the company has made across its three core pillars of corporate responsibility, namely People, Env...

Catalent Inc

Catalent Inc's Disappointing Performance: Unveiling the Culprits Behind Weak Sales in the Tragic December 2023 Quarter

Catalent Inc is a leading player in the pharmaceutical industry, specializing in the development and supply of advanced treatments for patients worldwide. Their recent financial results for the fiscal time-frame ending December 31, 2023, may have raised some concerns due to diminishing returns and a decrease in revenue. However, it is important to note that the company also reported an improvement in EPS and sequential revenue growth, showing that there is still momentum and potential for growth.
Despite the challenges faced by Catalent Inc in the past reporting season, the overall Major Pharmaceutical Preparations sector recorded a revenue growth of 3.59% in the second quarter of 2024. This indicates that the industry as a whole is still performing well, which could potentially benefit Catalent Inc in the long run.

Merger and Acquisition

Novo Holdings to Acquire Catalent: A Landmark Merger in the Pharmaceutical Industry

Published Mon, Feb 5 2024 11:00 AM UTC


In a recent press release, Catalent Inc. (NYSE: CTLT), a globally renowned company specializing in developing and supplying advanced treatments for patients worldwide, and Novo Holdings, a leading investment firm responsible for managing the assets and wealth of the Novo Nordisk Foundation, revealed their plans for a significant merger. Under this merger agreement, Novo...

Product Service News

Catalent's Commitment to Sustainability: A Step Towards Green Pharmaceutical Manufacturing

Published Thu, Jan 25 2024 5:00 PM UTC

Catalent, a leading global provider of solutions for the pharmaceutical and healthcare industries, has made a significant commitment to reducing greenhouse gas (GHG) emissions. The company aims to achieve a 42% reduction in Scope 1 and 2 emissions by 2030. Additionally, Catalent plans to collaborate with its suppliers to align 70% of their emissions reduction goals with scie...

Financing Agreement

Catalent Harnesses $600 Million in New Term Loans to Surge Forward Amidst Financial Hurdles

Published Tue, Dec 19 2023 9:15 PM UTC



In an effort to fortify its position as the global leader in developing and providing advanced treatments for patients worldwide, Catalent, Inc. recently announced a significant financial move. The company's wholly owned subsidiary, Catalent Pharma Solutions, Inc., has entered into an amendment to its existing credit agreement, paving the way for the issuance of ne...






 

Catalent Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com